Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Gresle

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Human Molecular Genetics|July 19, 2015
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosisBen J Gu, Judith Field, Sébastien Dutertre, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Neurology|April 21, 2021
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple SclerosisWei Zhen Yeh, Putu Ayu Widyastuti, Anneke Van der Walt, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Human Molecular Genetics|July 19, 2015
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosisBen J Gu, Judith Field, Sébastien Dutertre, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Neurology|April 21, 2021
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple SclerosisWei Zhen Yeh, Putu Ayu Widyastuti, Anneke Van der Walt, et al.
Pageof 3